Fig. 2.

Network diagrams of studies evaluating efficacy of antihyperglycemic agents in change from baseline in a HbA1c; b weight; c systolic blood pressure. Treatment dosages are presented as mg per day if not otherwise specified. All patients received metformin as background therapy. Only oral dosages approved in the US and EU were included in the network meta-analysis. Vilda is only approved in the EU, at 50 mg twice a day (bid). Vilda is not approved in the US. Alo alogliptin, bid twice a day, Cana canagliflozin, Dapa dapagliflozin, Empa empagliflozin, Ertu ertugliflozin, EU, Europe, Exen exenatide, Glim glimepiride, Lina linagliptin, Lira liraglutide, PBO placebo, Saxa saxagliptin, Sema semaglutide, Sita sitagliptin, US United States, Vilda vildagliptin